Controlled study of hepatitis B virus level alteration in hepatocellular carcinoma while treating with transcatheter arterial chemoembolisation alone or in combination with interferon-alpha
ISRCTN | ISRCTN85736336 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN85736336 |
Secondary identifying numbers | N/A |
- Submission date
- 10/01/2009
- Registration date
- 15/05/2009
- Last edited
- 15/05/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Maoquan Li
Scientific
Scientific
Interventional Department
Affiliated 10th People's Hospital of Tongji University
No. 301 Middle Yanchang Road
Shanghai
200072
China
cjr.limaoquan@vip.163.com |
Study information
Study design | Randomised controlled non-blinded single-centre study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Controlled study of hepatitis B virus level alteration in hepatocellular carcinoma: monotherapy with transcatheter arterial chemoembolisation versus double therapy with transcatheter arterial chemoembolisation and interferon-alpha: a randomised controlled trial |
Study objectives | Hepatitis B virus (HBV) has been proved as one principal inducer of hepatiocellular carcinoma (HCC) by epidemiology study and animal experiment. And for many unresectable HCC, transcatheter arterial chemoembolism (TACE) is the most effective way to relieve the disease and elongate life. However, some studies have revealed that TACE may reactivate HBV replication and result in worse prognosis in HCC patients. Some evidences show that interferon-alpha (IFN-a) can reduce HBV level effectively and safely. In addition, IFN-a has also been proved a worthful therapy to HBV-related HCC with postponed recurrence and prolonged life time. We assume that at the same time of TACE treatment, administration of IFN-a may suppress the reactivation of HBV replication. To test our assumption, we designed a randomised controlled study in HCC patients with positive hepatitis B surface antigen (HBS-Ag) and hepatitis B e antigen (HBe-Ag) to evaluate the efficacy of HBV inhibition and survival by double therapy with TACE and IFN-a versus monotherapy with TACE. |
Ethics approval(s) | Ethics Committee of the Affiliated 10th People's Hospital, Tongji University, approved in October 2008 (ref: 08-10-5). |
Health condition(s) or problem(s) studied | Hepatitis B virus related hepatocellular carcinoma |
Intervention | All included patients will be divided into two groups by randomisation. One group will receive double therapy with TACE and IFN-a, while the other group will receive monotherapy with TACE as control. A 0.2% emulsion of epirubicin mixed with lipiodine (GUERBET™) is used for TACE in both groups. IFN-a is administered at a dosage of 60 ug every other day for a duration of 6 months. The frequency and total duration of TACE therapy for each group is once per month and 3 times in total. Follow-up for HBV-DNA level, survival and progress free survival (PFS) will last for 6 months. |
Intervention type | Other |
Primary outcome measure | 1. HBV reactivation, defined as a greater than 10-fold increase in serum HBV-DNA compared with the baseline level 2. Hepatitis due to HBV reactivation, defined as a threefold or greater increase in serum ALT to a level that exceeded 100 IU/L (reference range less than 33 IU/L) in patients with HBV reactivation in the absence of clinical features of tumour progression, hepatotoxic drugs, treatment-related hepatic damage, or other systemic infections 3. Disease progress, according to the Response Evaluation Criteria in Solid Tumors (RECIST) standard 4. Patient death The outcomes above will be measured every month after the end of therapy until 6 months. |
Secondary outcome measures | Severe complications: unendurable fever, hepatic decompensation, measured every month after the end of therapy until 6 months. |
Overall study start date | 01/12/2008 |
Completion date | 01/09/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 116 |
Key inclusion criteria | 1. Image or pathologically diagnosed HCC 2. Newly diagnosed HCC 3. Unresectable HCC 4. Positive serum HBS-Ag and HBe-Ag 5. Child-Pugh scale A and B 6. Older than 20 years, either sex 7. Patients without jaundice |
Key exclusion criteria | 1. Previous history of antiviral therapy 2. Baseline serum alanine aminotransferase (ALT) level 2.5 times the upper limit of normal or higher 3. Serum HBV DNA level greater than 107 copies/mL 4. Main portal vein thrombosis 5. Underlying cardiac or renal diseases 6. Positive tests for antibody to hepatitis C virus or human immunodeficiency virus 7. ChildPugh classification C 8. Pre-existing evidence of hepatic decompensation |
Date of first enrolment | 01/12/2008 |
Date of final enrolment | 01/09/2009 |
Locations
Countries of recruitment
- China
Study participating centre
Interventional Department
Shanghai
200072
China
200072
China
Sponsor information
Affiliated 10th People's Hospital of Tongji University (China)
Hospital/treatment centre
Hospital/treatment centre
No. 301 Middle Yanchang Road
Shanghai
200072
China
Website | http://www.shdsyy.com.cn |
---|---|
https://ror.org/03vjkf643 |
Funders
Funder type
Hospital/treatment centre
Affiliated 10th People's Hospital of Tongji University (China)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |